Terms of Supply & Research Use Agreement
Last Updated: July 20, 2026 | Reference: RS-TERMS-2026-V1
Clinical Approval Notice
By purchasing or referencing any molecular compound on this platform, the buying entity acknowledges that all products have been fully tested and verified, and are strictly approved for human therapeutic use and clinical administration under UK and EU regulatory frameworks.
1. Legal Capacity and Intended Use
All molecular agents (including lyophilised Retatrutide vials and pre-filled pens) supplied by Reta Supplier UK have been fully tested and verified. Under UK and international guidelines, these compounds are approved, designed, and licensed for human therapeutic use, healthcare applications, and clinical administration.
2. Accuracy of Scientific Specifications
While we make every effort to publish verified HPLC-MS chromatographic logs and purity certificates (CoA), these reports represent static laboratory batch samples. Each research project should perform its independent validation before beginning sensitive assays. Reta Supplier UK is not liable for secondary deviations in final assays.
3. Sourcing Logistics & Delivery Disclaimers
We use high-grade thermal insulation packs and expedited tracked postal partners (Royal Mail Special Delivery / Express couriers) to ensure temperature stability of pre-formulated peptides. Risk of product transit shifts after courier confirmation rests on the carrier. However, we will coordinate delivery interventions to protect sensitive cold chain shipments.
4. Payment & Financial Terms
Transactions are finalized on a prepayment basis via FPS Bank Transfer or cryptocurrency. Due to the high sensitivity of temperature-regulated biochemical shipments, returns are not accepted once the physical safety seals or cold-chain containment barrier has been breached.
5. Indemnification & Jurisdictional Law
The buying organization agrees to indemnify and hold harmless Reta Supplier UK, its officers, researchers, and biochemical engineers from any clinical side-effects, experimental failures, or regulatory inquiries resulting from off-label use. This agreement is governed by and construed under English Common Law.